2022
DOI: 10.1182/blood-2022-159369
|View full text |Cite
|
Sign up to set email alerts
|

Budget Impact Analysis of the Use of Gilteritinib for the Treatment of Patients with Relapsed or Refractory FLT3+ Acute Myeloid Leukaemia in Public Healthcare Institutions in Mexico

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles